<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289678</url>
  </required_header>
  <id_info>
    <org_study_id>LJCC 06-05</org_study_id>
    <nct_id>NCT01289678</nct_id>
  </id_info>
  <brief_title>Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia</brief_title>
  <official_title>Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leo W. Jenkins Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leo W. Jenkins Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment
      during lymphocyte recovery.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to meet accrual goals
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Event-free survival (EFS) = all patients; measured from the date of entry onto study until treatment failure, AML relapse, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient response</measure>
    <time_frame>10 years</time_frame>
    <description>Response:
Morphologic Complete Remission (CR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interleukin-2 therapy during lymphocyte recovery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days</description>
    <arm_group_label>interleukin-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment

          -  Total WBC recovery of 500 mm3 prior to IL-2 treatment

          -  Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment

          -  Active infection controlled prior to starting IL-2 treatment

          -  Stable systolic blood pressure &gt; 90mm Hg prior to starting IL-2 treatment

          -  O2 saturation &gt;90% prior to starting treatment

          -  Stable cardiopulmonary status prior to starting IL-2 treatment

          -  Serum creatinine &lt; or equal to 2.0 mg/dl

          -  Total bilirubin and AST &lt;3x upper limits normal

        Exclusion Criteria:

          -  Acute Promyelocytic Leukemia

          -  Active thrombocytopenic bleeding

          -  Cardiac ejection fraction below 45%

          -  Pregnancy and/or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Walker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Brody School of Medicine at East Carolina University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2011</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myelogenous leukemia</keyword>
  <keyword>interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

